RNatives develops RNA-based therapies for cardiovascular diseases, focusing on RNA activation of VEGFA.
RNatives has raised $1.6M in total funding. The most recent round was Seed. The last funding was announced in May 2025.
RNatives's investors include Nordic Science Investments, Business Finland, Force 10 Partners.
RNatives is headquartered in Kuopio, Finland.
RNatives develops RNA-based therapies for cardiovascular diseases, focusing on RNA activation of VEGFA.
RNatives is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RNatives — Funding & Investors." VCBacked, May 27, 2025, https://www.vcbacked.co/company/rnatives. Accessed September 15, 2026.
VCBacked. (2025). RNatives — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/rnatives
{{cite web |title=RNatives — Funding & Investors |url=https://www.vcbacked.co/company/rnatives |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated